Use the Search Fields to Find Information
Page 78 of 365
Ratings of executive function as a risk factor for adolescents’ frequent cannabis use: A prospective longitudinal study
Please use this link to access this publication: https://psycnet.apa.org/record/2023-16721-001 Abstract Objective: We examined the extent to which behavioral ratings of children’s executive function (EF) in early
November 29, 2023
Rates of Prenatal Cannabis Use Among Pregnant Women Before and During the COVID-19 Pandemic
ABSTRACT Cannabis use among pregnant women is common and has increased in recent years in the US, from an estimated 3.4% in 2002 to
September 6, 2025
Rates and correlates of cannabis-associated psychotic symptoms in over 230,000 people who use cannabis
Abstract Cannabis, a widely used psychoactive substance, can trigger acute cannabis-associated psychotic symptoms (CAPS) in people who use cannabis (PWUC). To assess rates and correlates
February 29, 2024
Rate of cannabis use in older adults with cancer
Please use this link to access this publication. Abstract Objectives Older adults with cancer are increasingly inquiring about and using cannabis. Despite this, few studies have
February 28, 2024
Rare but relevant: Cannabis use and myocardial infarction
Abstract Pre-clinical research and case reports have linked cannabis use to myocardial infarction (MI) since the 1970s. The association with MI may be specific to
November 20, 2025
Rare but relevant: Cannabinoid hyperemesis syndrome
Please use this link to access this publication. Abstract Cannabinoid hyperemesis syndrome (CHS) is a (probably) rare syndrome that occurs in frequent and chronic cannabis
February 1, 2026
Randomized, placebo-controlled, 28-day safety and pharmacokinetics evaluation of repeated oral cannabidiol administration in healthy dogs
OBJECTIVE To determine the safety and pharmacokinetics of various doses of plant- derived cannabidiol (CBD) versus placebo following repeated oral administration. ANIMALS 20 healthy adult
October 28, 2021
Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis
Background: Central pain in multiple sclerosis (MS) is common and often refractory to treatment. Methods: We conducted a single-center, 5-week (1-week run-in, 4-week treatment), randomized,
September 19, 2019
Randomized Placebo-Controlled Double-Blind Clinical Trial of Cannabis-Based Medicinal Product (Sativex) in Painful Diabetic Neuropathy: Depression is a major confounding factor
OBJECTIVE To assess the efficacy of Sativex, a cannabis-based medicinal extract, as adjuvant treatment in painful diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS In
October 7, 2024
Randomized Laboratory Study of Single-Dose Cannabis, Dronabinol, and Placebo in Patients With Schizophrenia and Cannabis Use Disorder Get access Arrow
Please use this link to access this publication. Abstract Background and Hypothesis Up to 43% of people with schizophrenia have a lifetime cannabis use disorder
September 5, 2024
Page 78 of 365